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ABSTRACT 
The purpose of this study was to determine whether the treatment with recombinant plasmid 
consisted of human GLP1 promoter and insulin gene can treat diabetic rats. Rats were 
induced type-1 diabetes mellitus (T1DM) by a single dose of intraperitoneal injection of 
streptozotocin (STZ) at dose of 55mg/kg. The induction of diabetes was confirmed in rats by 
checking the blood glucose level for seven days. The recombinant plasmid, GLP1/Ins/pBud 
plasmid, was wrapped with chitosan and then transferred to diabetic rats by force feeding. 
The blood glucose level was checked from the tips of the tails by needle puncture using a 
glucometer and test strips. The blood levels of human and rat insulin were assessed by 
enzyme-linked immunosorbent assay (ELISA). The results showed no significant effects of 
orally  treatment  with  recombinant plasmid DNA at both doses of 100 and 600 μg/mL of the 
human insulin level in diabetic  rats (p>0.05). The human insulin level was significantly 
increased by orally treatment at dose of 300 μg/mL (p=0.04).  The findings indicated that the 
intraperitoneal injection of 300 μg/mL of this nanoparticle complex prominently increased 
the human insulin level in diabetic rats in contrast to both doses of 100 and 600 μg/mL. 
Despite above results, both methods was not effective enough to decrease the blood glucose 
levels in diabetic rats. It was concluded that the treatment of diabetic rats with recombinant 
plasmid consisted of human GLP1 promoter and insulin gene was not effective to reduce the 
blood glucose levels in diabetic rats. 
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